Tuesday, October 22, 2019 9:32:40 AM
"One other thing I'll mention is that I did have a conversation with DOC (Dan O'Connor) several months ago. When I asked him about Merck's interest in ONCS, DOC basically said that Merck likes the data, but would only move forward to pull the trigger on a bigger deal (monetary partnership or buyout) if they "had to". When I asked follow-up questions, the response was … that's just the way Merck does their business development... they don't make major moves unless they feel someone else is interested, and their hand is forced.
IMO, this deal with CGP is DOC's way of forcing Merck to make a decision. I'm going to hold until we see how the story ends. I think it ends higher than $4.50 with multiple parties appearing to be interested (Alpha, CGP and Merck) and the institutional investors still holding."
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM